WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced that the US Patent and Trademark Office (USPTO) has allowed the issuance of a Selecta owned patent with the title “Tolerogenic Synthetic Nanocarriers For Inducing Regulatory B Cells”, the first in a series of patent filings on antigen-specific tolerogenic immunotherapies.
Help employers find you! Check out all the jobs and post your resume.
